Rami Skaliter, M.Sc., Ph.D., is the CEO of Cell Cure Neurosciences, a majority-owned (>95%) Israeli subsidiary of BioTime. The site is focused on manufacturing and related research and development activities. Dr. Skaliter was appointed in June 2017. In his last position, Dr. Skaliter worked for ten years as the Chief Operating Officer of Quark Pharmaceuticals, a late-stage pharmaceutical company developing siRNA-based novel therapeutics. Previously, Dr. Skaliter held various corporate and research executive positions at Quark Pharmaceuticals. Dr. Skaliter obtained his B.Sc. in Biology at the Ben-Gurion University and his M.Sc. and Ph.D. in Biochemistry at the Weizmann Institute in Israel. He specialized in the biochemistry of replication and mutagenesis mechanisms. Between 1993 and 1995, prior to joining Quark, Dr. Skaliter completed a post-doctoral fellowship at Stanford University. Dr. Skaliter serves as a director of Tikcro Technologies Ltd., a public company developing therapeutic antibodies.